S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
State of the Union: Biden sees economic glow, GOP sees gloom
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Tesla hikes price of Model Y after US alters tax credit rule
Disney World unions vote down offer covering 45,000 workers
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Iraqi currency crash halts after meeting with U.S. official
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Gas prices dip in NJ, around nation as cold weather returns

Fate Therapeutics - FATE Stock Forecast, Price & News

$6.87
+0.04 (+0.59%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$6.40
$6.95
50-Day Range
$4.24
$20.91
52-Week Range
$4.02
$43.12
Volume
3.28 million shs
Average Volume
5.13 million shs
Market Capitalization
$667.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.75

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.18 Rating Score
Upside/​Downside
333.0% Upside
$29.75 Price Target
Short Interest
Healthy
16.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.53mentions of Fate Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$698,138 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.22) to ($2.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.81 out of 5 stars

Medical Sector

27th out of 1,028 stocks

Biological Products, Except Diagnostic Industry

5th out of 168 stocks

FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks? (FATE)
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock? (FATE)
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Analyst Ratings for Fate Therapeutics
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
11/04/2021
Today
2/05/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.75
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+333.0%
Consensus Rating
Hold
Rating Score (0-4)
2.18
Research Coverage
22 Analysts

Profitability

Net Income
$-212,150,000.00
Net Margins
-425.99%
Pretax Margin
-425.99%

Debt

Sales & Book Value

Annual Sales
$55.85 million
Book Value
$7.11 per share

Miscellaneous

Free Float
80,321,000
Market Cap
$667.56 million
Optionable
Optionable
Beta
1.46

Key Executives

  • J. Scott WolchkoJ. Scott Wolchko
    President, Chief Executive Officer & Director
  • Edward J. DulacEdward J. Dulac
    Chief Financial Officer & Accounting Officer
  • Bahram ValamehrBahram Valamehr
    Chief Research & Development Officer
  • Wen Bo Wang
    Senior Vice President-Technical Operations
  • Yu Waye ChuYu Waye Chu
    Chief Medical Officer













FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 sell ratings, 14 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2023?

22 Wall Street analysts have issued 1-year price targets for Fate Therapeutics' shares. Their FATE share price forecasts range from $7.00 to $90.00. On average, they expect the company's share price to reach $29.75 in the next year. This suggests a possible upside of 333.0% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 at the beginning of 2023. Since then, FATE shares have decreased by 31.9% and is now trading at $6.87.
View the best growth stocks for 2023 here
.

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 15,450,000 shares, a decline of 30.8% from the December 31st total of 22,330,000 shares. Based on an average daily trading volume, of 3,130,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 16.9% of the company's shares are short sold.
View Fate Therapeutics' Short Interest
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.58) by $0.13. The biopharmaceutical company had revenue of $14.23 million for the quarter, compared to analyst estimates of $8.67 million. Fate Therapeutics had a negative net margin of 425.99% and a negative trailing twelve-month return on equity of 48.78%. The firm's revenue was up 88.3% on a year-over-year basis. During the same period last year, the firm earned ($0.36) EPS.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (4.34%), Sumitomo Mitsui Trust Holdings Inc. (0.93%), Monaco Asset Management SAM (0.26%), Rice Hall James & Associates LLC (0.22%), Comerica Bank (0.14%) and State of New Jersey Common Pension Fund D (0.12%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $6.87.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $667.56 million and generates $69.01 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 449 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 2/5/2023 by MarketBeat.com Staff